Crohn’s Disease Treatment Market Forecast Highlights Expansion From $13.98 Billion To $18.85 Billion Through 2030
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Crohn’s Disease Treatment Market Expected To Reach $18.85 Billion By 2030 At 7.8% CAGR
The market for Crohn’s disease treatment has experienced substantial expansion over recent years. Projected to rise from $13.1 billion in 2025 to $13.99 billion in 2026, this growth reflects a compound annual growth rate (CAGR) of 6.8%. Historically, this upward trend has been driven by factors such as a higher prevalence of Crohn’s disease, greater public awareness surrounding inflammatory bowel conditions, the broadening reach of hospital pharmacy networks, the continued availability of conventional anti-inflammatory medications, and enhancements in diagnostic technologies.
The Crohn’s disease treatment market is projected to experience substantial growth in the coming years. By 2030, its value is anticipated to reach $18.86 billion, expanding at a compound annual growth rate (CAGR) of 7.8%. This forecasted growth is driven by an expanding pipeline of biologics and small molecules, a growing demand for tailored treatment approaches, increased penetration of online pharmacies, rising healthcare spending in developing nations, and a greater emphasis on long-term disease management. Key trends shaping the market during this period include the growing adoption of biologic therapies, a shift toward earlier and more aggressive treatment strategies, an increased focus on minimizing steroid use, the emergence of oral small-molecule treatments, and the expansion of both online and specialty pharmacy channels.
Download A Free Sample Report For Comprehensive Market Insights:
Crohn’s Disease Treatment Market Expansion Supported By Key Demand Factors
The growing frequency of inflammatory bowel disorders is set to drive the Crohn’s disease treatment market forward. These disorders are chronic conditions marked by inflammation of the gastrointestinal tract, potentially damaging any part of the digestive system from the mouth to the anus. Treatment with Crohn’s disease therapies works by reducing intestinal inflammation, preventing symptom flare-ups, and maintaining remission. For example, in September 2023, the National Center for Biotechnology Information, a US-based government body, reported that the prevalence of Crohn’s disease and ulcerative colitis has risen similarly, with inflammatory bowel disease estimated at 825 cases per 100,000 people in 2023—410 for Crohn’s disease, 414 for ulcerative colitis, and IBD-u. Consequently, the increasing prevalence of these conditions is driving growth in the market for Crohn’s disease treatments.
Crohn’s Disease Treatment Market Categorization By Product Type And Application
The crohn’s disease treatment market covered in this report is segmented –
1) By Drug Type: Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, Other Drug Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Neuropathic Pain, Fibromyalgia, Chronic Back Pain, Arthritic Pain, Migraine Post-Operative Pain, Cancer Pain, Other Applications
Subsegments:
1) By Antibiotics: Metronidazole, Ciprofloxacin, Other Antibiotics
2) By Amino Salicylates: Mesalamine, Sulfasalazine, Other Amino Salicylates
3) By Corticosteroids: Prednisone, Budesonide, Other Corticosteroids
4) By Immunomodulators: Azathioprine, Methotrexate, Mercaptopurine
5) By Other Drug Types: Biologics, Small Molecules, Other Treatments
Crohn’s Disease Treatment Market Growth Trends Influencing Competitive Dynamics
Leading industry players in the Crohn’s disease treatment market are continuously developing and securing regulatory approval for new therapies, including biosimilar ustekinumab, with the goal of delivering more effective and accessible options to patients, thereby enhancing clinical results and overall quality of life. A biosimilar version of ustekinumab is a biologic medicine that closely resembles the original ustekinumab, a monoclonal antibody employed in treating autoimmune disorders. As an example, during July 2024, Sandoz International GmbH, a pharmaceutical firm headquartered in Switzerland, introduced Pyzchiva (ustekinumab) throughout Europe, establishing it as the first ustekinumab biosimilar offered in all dosage forms, which encompasses a 130 mg vial tailored for Crohn’s disease. This treatment is indicated for individuals aged six and older suffering from plaque psoriasis, psoriatic arthritis, and Crohn’s disease, thereby strengthening Sandoz’s immunology portfolio and working to expand access to cost-effective therapies for chronic inflammatory conditions.
Crohn’s Disease Treatment Market Company Landscape And Strategic Competition
Major companies operating in the crohn’s disease treatment market are AbbVie Inc., Janssen Pharmaceuticals, Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Galapagos NV, Teva Pharmaceutical Industries Ltd., Mylan N.V., Glenmark Pharmaceuticals, Tillotts Pharma AG, Dr. Falk Pharma GmbH, Shire Pharmaceuticals, Salix Pharmaceuticals, Prometheus Laboratories Inc., Pfizer Inc., Novartis AG, Sanofi S.A., Eli Lilly and Company, Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd.
Access The Complete Crohn’s Disease Treatment Market Report:
Crohn’s Disease Treatment Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the global Crohn’s disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the crohn’s disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
